All In Biotech

Drug Trial Radar · NCT04082429

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

156

Actual

Start

Nov 13, 2019

Primary completion

Jul 12, 2022

Study completion Feb 21, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleeds (on-demand) will be placed in one of two groups. In one group participants will get study medicine from the start of the study. In the other group participants will continue with their normal medicine and get study medicine after 6 months. Which treatment the participant gets is decided by chance. Participants who usually take medicine to prevent bleeds (prophylaxis treatment) or who are already being treated with concizumab (study medicine) will receive the study medicine from the start of the study. Participants will have to inject themselves with the study medicine 1 time every day under the skin. This can be done at home. The study doctor will hand out the medicine in the form of a pen-injector. The pen-injector will contain the study medicine. The study will last for up to 8 years. The length of time the participant will be in the study depends on when they agreed to take part and when the medicine is available for purchase in their country (or 31 December 2027 at the latest). The time between visits will be approximately 4 weeks for the first 6 to 12 months depending on the group participants are in, and approximately 8 weeks for the rest of the study. If the participant attends extra visits due to the prescription medicine not being available for purchase in their country, these will be 14 weeks apart. Participants will be asked to record information in an electronic diary during the study and may also be asked to wear an activity tracker.

Conditions

  • Haemophilia A Without Inhibitors
  • Haemophilia B Without Inhibitors

Interventions

  • ConcizumabDrug

    When patients are randomised/allocated to concizumab prophylaxis, they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week (Wk) 0) (arm 2, 3 and 4) or visit 9a (Wk 24) (arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (Wk 6) or 9a.3 (Wk 30) and will be based on the concizumab exposure level measured at the previous visit 4a (Wk 6) or 9a.2 (Wk 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual replacement therapy until visit 9a (week 24; end of main part). In the extension part, patients in arm 1 will receive daily concizumab subcutaneous injections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Haemophilia A Participants Without Inhibitors: Rate of Treated Spontaneous and Traumatic Bleeding EpisodesTime frame: On demand (arm 1): From week 0 up until start of concizumab treatment (week 24); Concizumab (arm 2): From week 0 up until the confirmatory analyses cut-off
  2. Haemophilia B Participants Without Inhibitors: Rate of Treated Spontaneous and Traumatic Bleeding EpisodesTime frame: On demand (arm 1): From week 0 up until start of concizumab treatment (week 24); Concizumab (arm 2): From week 0 up until the confirmatory analyses cut-off

Locations

113 sites in 33 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles - Endocrinology

    Los Angeles, California

  • Center for Inherited Blood Disorders

    Orange, California

  • Center for Blood Disorders Augusta University

    Augusta, Georgia

  • Indiana Hemophilia-Thromb Ctr

    Indianapolis, Indiana

  • University of Iowa_Iowa City

    Iowa City, Iowa

  • Children's Hospital of Michigan

    Detroit, Michigan

  • Michigan State University

    Lansing, Michigan

  • Novant Hlth Vasc Ins Charlotte

    Charlotte, North Carolina

  • M.S. Hershey Medical Center

    Hershey, Pennsylvania

  • Vanderbilt University Medical Center_Nashville_0

    Nashville, Tennessee

  • University of Texas San Antonio

    San Antonio, Texas

  • Versiti, CCBD

    Milwaukee, Wisconsin

  • Haematology and Blood Bank Department

    Algiers, Algeria

  • CHU Constantine BEN BADIS/ Hematology department

    Constantine, Algeria

  • The Alfred

    Melbourne, Victoria, Australia

  • Royal Children's Hospital

    Parkville, Victoria, Australia

  • The Royal Children's Hospital

    Parkville, Victoria, Australia

  • Fiona Stanley Hospital - Haemophilia and Haemostasis Centre

    Murdoch, Western Australia, Australia

  • University Clinical Center of Republic Srpska (205)

    Banja Luka, Bosnia and Herzegovina

  • UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology

    Sofia, Bulgaria

  • UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology

    Varna, Bulgaria

  • Eastern Health Authority

    St. John's, Newfoundland and Labrador, Canada

  • Hamltn Hth Sci/McMstr Child Hosp

    Hamilton, Ontario, Canada

  • KBC Zagreb_Hematology

    Zagreb, Croatia

  • Copenhagen Center for Heamatology

    Copenhagen, Denmark

  • North Estonia Medical Centre Foundation

    Tallinn, Estonia

  • Centre Hospitalier Regional Et Universitaire de Brest-Hopital de La Cavale Blanche

    Brest, France

  • CHU de Caen - Côte de Nacre

    Caen, France

  • Hopital de Bicetre

    Le Kremlin-Bicêtre, France

  • Centre Hospitalier Universitaire de Nantes-Hopital Hotel-Dieu

    Nantes, France

  • Hôpital Pontchaillou

    Rennes, France

  • Centre Hospitalier Universitaire de Saint Etienne-Hopital Nord

    Saint-Priest-en-Jarez, France

  • Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie

    Bonn, Germany

  • Universität des Saarlandes - Hämostaseologie und Transfusionsmedizin

    Homburg, Germany

  • MH Eü. Központ -Orszagos Haemophilia Kozpont

    Budapest, Hungary

  • St. John's Medical college and Hospital

    Bangalore, Karnataka, India

  • Sahyadri Speciality Hospital

    Pune, Maharashtra, India

  • Sahyadri Super Speciality Hospital

    Pune, Maharashtra, India

  • J K Lon Hospital

    Jaipur, Rajasthan, India

  • CMCV

    Ranipet, Tamil Nadu, India

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.